Risk comparison of adverse reactions between gemcitabine monotherapy and gemcitabine combined with albumin-bound paclitaxel in pancreatic cancer: insights from the FDA Adverse Event Reporting System (FAERS) database
This research offers critical safety insights in real-world settings, emphasizing patients at heightened AEs risk and informing clinical decision-making in PC treatment.
Authors
- Puen Jiang (ORCID: https://orcid.org/0000-0002-7824-6874)
- Zhongjun Wu (ORCID: https://orcid.org/0000-0002-1627-0633)
- Dadi Peng
- Kezhen Zong (ORCID: https://orcid.org/0000-0003-2233-5488)
- Baoyong Zhou (ORCID: https://orcid.org/0000-0002-8022-982X)
Institutions
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- BMC Pharmacology and Toxicology
- Published
- 2025-03-19
- DOI
- https://doi.org/10.1186/s40360-025-00884-5
- Citations
- 2
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 2.09